🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being hailed as a "major milestone" in the battle against superbug strains of the pathogen, according to health experts.

A Worldwide Public Health Issue

Gonorrhoea infections are increasing around the world, with figures suggesting over 82 million infections annually. Notably increased rates are observed in the African continent and countries within the WHO's designated area, which includes China and Mongolia to New Zealand. In England, cases have hit a all-time high, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The authorization of new treatments for gonorrhoea is an critical and opportune advancement in the context of increasing worldwide cases, escalating drug resistance and the very limited available drugs currently available.”

Public health authorities are increasingly worried about the surge in drug-resistant strains. The WHO has classified it as a "high-priority threat". Ongoing monitoring revealed that resistance to standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Therapies Gain Clearance

One new antibiotic, marketed under the name Nuzolvence, was approved by the US Food and Drug Administration in mid-December for treating gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Scientists hope that targeted use of this new drug will help delay the development of resistance.

Gepotidacin, originating from the drugmaker GlaxoSmithKline, also received approval in close succession. This medication, which is also used to treat urinary tract infections, was shown in trials to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin was the result of a unique collaborative effort for medication research. The charitable organization GARDP partnered with the drug firm its industry partner to develop it.

“This approval marks a major breakthrough in the therapy of multidrug-resistant gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Testing Results and Global Access

According to results detailed in a prominent scientific publication, the new drug cured over nine in ten of cases of the STI. This puts it on an similar efficacy with the existing first-line therapy, which combines two antibiotics. The research involved hundreds of volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, GARDP has the rights to register and commercialise the drug in numerous low-income and middle-income countries.

Medical professionals on the front lines have voiced optimism. Having a single-dose, oral treatment of this kind is seen as a "game-changer" for public health efforts. This is deemed crucial to lessen the impact of the infection for people and to prevent the spread of highly drug-resistant gonorrhoea worldwide.